Cargando…
The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews
AIMS: To summarize reported cancer events associated with SGLT‐2 inhibitors used in patients with type 2 diabetes mellitus, as well as assess the quality of included reviews. MATERIALS AND METHODS: In May 2019, we searched PubMed, Embase and the Cochrane Library for quantitative systematic reviews a...
Autores principales: | Pelletier, Ryan, Ng, Kelvin, Alkabbani, Wajd, Labib, Youssef, Mourad, Nicolas, Gamble, John‐Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375059/ https://www.ncbi.nlm.nih.gov/pubmed/32704566 http://dx.doi.org/10.1002/edm2.145 |
Ejemplares similares
-
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
por: Pelletier, Ryan, et al.
Publicado: (2021) -
Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study
por: Alkabbani, Wajd, et al.
Publicado: (2021) -
Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus
por: Alkabbani, Wajd, et al.
Publicado: (2022) -
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)